Literature DB >> 697950

Herpes zoster in patients with systemic lupus erythematosus.

H M Moutsopoulos, J D Gallagher, J L Decker, A D Steinberg.   

Abstract

In the context of prospective trials of immunosuppressive drugs in systemic lupus erythematosus (SLE) nephritis, 83 patients were studied with regard to development of herpes zoster. Herpes zoster was found to occur with high frequency (21%) in patients with SLE nephritis treated with immunosuppressive agents. The course of herpes zoster was benign: no deaths occurred and only 2 of the 18 patients developed generalized disease, which resolved without sequelae. Specific antiviral therapy was not necessary and there appears to be no need to decrease immunosuppressive medications. Zoster occurred when the SLE was relatively inactive and did not exacerbate the SLE. No statistical difference in the incidence of zoster was found among the patient groups treated with different immunosuppressive regimens.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 697950     DOI: 10.1002/art.1780210710

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  9 in total

1.  The case for Zostavax vaccination in systemic lupus erythematosus.

Authors:  Abigail R Cogman; Eliza F Chakravarty
Journal:  Vaccine       Date:  2013-06-03       Impact factor: 3.641

2.  High incidence of herpes zoster in patients with systemic lupus erythematosus: an immunological analysis.

Authors:  K Nagasawa; Y Yamauchi; Y Tada; T Kusaba; Y Niho; H Yoshikawa
Journal:  Ann Rheum Dis       Date:  1990-08       Impact factor: 19.103

Review 3.  Vaccination of patients with autoimmune inflammatory rheumatic diseases.

Authors:  Johanna Westra; Christien Rondaan; Sander van Assen; Marc Bijl
Journal:  Nat Rev Rheumatol       Date:  2014-12-09       Impact factor: 20.543

4.  Feasibility and validity were demonstrated of an online case-control study using the prototype of recent-onset systemic lupus erythematosus.

Authors:  Timothy McAlindon; Jun Wang; Margaret Formica; Ashley Kay; Hocine Tighiouart; Christine Chaisson; Jeremiah Fletcher
Journal:  J Clin Epidemiol       Date:  2008-03-14       Impact factor: 6.437

5.  Herpes zoster vaccination in SLE: a pilot study of immunogenicity.

Authors:  Joel M Guthridge; Abigail Cogman; Joan T Merrill; Susan Macwana; Krista M Bean; Tiny Powe; Virginia Roberts; Judith A James; Eliza F Chakravarty
Journal:  J Rheumatol       Date:  2013-09-15       Impact factor: 4.666

6.  Herpes Zoster Infections in SLE in a University Hospital in Saudi Arabia: Risk Factors and Outcomes.

Authors:  Afsar Sayeeda; Hussain Al Arfaj; Najma Khalil; A S Al Arfaj
Journal:  Autoimmune Dis       Date:  2010-09-13

7.  Risk of Herpes zoster in patients with underlying diseases: a retrospective hospital-based cohort study.

Authors:  A Hata; M Kuniyoshi; Y Ohkusa
Journal:  Infection       Date:  2011-07-29       Impact factor: 3.553

8.  Clinical and genetic risk factors of herpes zoster in patients with systemic lupus erythematosus.

Authors:  Tae-Young Kang; Hye-Soon Lee; Tae-Hwan Kim; Jae-Bum Jun; Dae-Hyun Yoo
Journal:  Rheumatol Int       Date:  2003-10-31       Impact factor: 3.580

9.  Risk of Herpes Zoster in Individuals on Biologics, Disease-Modifying Antirheumatic Drugs, and/or Corticosteroids for Autoimmune Diseases: A Systematic Review and Meta-Analysis.

Authors:  Fawziah Marra; Elaine Lo; Viktor Kalashnikov; Kathryn Richardson
Journal:  Open Forum Infect Dis       Date:  2016-09-28       Impact factor: 3.835

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.